{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"97"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as time from the date of first dose of rucaparib to the date of death due to any cause. Patients without a known date of death were to be censored on the date the patient was last known to be alive. A Kaplan-Meier analysis of OS was planned, however, due to early study termination and limited duration of OS follow-up, a descriptive summary of total deaths are presented. This includes deaths recorded on study (from first dose of study drug until 28 days after last dose of study drug), and deaths recorded in long-term follow-up (from last dose +28 days until death, loss to follow-up, withdrawal of consent, or study closure).","groups":[{"description":"Patients with HRD status unknown who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor genome-wide LOH was not tested or not determined were considered HRD unknown.","id":"OG000","title":"HRD Unknown"},{"description":"Patients with HRD status negative who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH \\< 10% were considered HRD-negative.","id":"OG001","title":"HRD Negative"},{"description":"Patients with HRD status positive who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH ≥ 10% were considered HRD-positive.","id":"OG002","title":"HRD Positive"},{"description":"All patients","id":"OG003","title":"Overall"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat population - all patients who received at least 1 dose of rucaparib","reportingStatus":"POSTED","timeFrame":"The total study time for reporting of deaths was approximately 19 months.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}